Determining Serum & Urinary Levels of miRNA 192 & miRNA 25 in Patients

Status Completed

Clinical Trial Summary

Diabetes kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in western countries and its incidence is worryingly increasing worldwide. Cardiovascular disease shows a continuous relationship with declining of renal function in type 2 diabetes patients. Moreover, there is a strong evidence of all-cause mortality risk excess even in patients with early stages kidney disease.

MicroRNA (miRNA) are small non-coding RNA molecules, containing 21-25 nucleotides, that modulate post-transcriptional gene expressions. In the past years many human miRNAs involved in the pathogenesis of renal disease have been discovered, such as miR-192, miR-194, miR-204 and miR-25. Among these, miR-192 and miR-25, are receiving greater attention while it seems that they play a role in glomerulosclerosis and renal fibrosis. However too few data are available in large publish trials among patients with renal impairment and the role of serum and urinary levels of miR-192 and miR-25 in people with preserved renal function remain unclear.

To evaluate the association between serum and urinary expression of miR-192 and miR-25 and renal function (according to different extent of renal impairment) in patients with or without type 2 diabetes.

Clinical Trial Description

The day of the study patients undergo a routine clinical evaluation. Whole blood samples are collected from an antecubital vein to assess serum/plasma aliquots of 200 μl each (frozen at -80°C until required for quantitation) for evaluation of biochemical parameters (fasting glucose, HbA1c, lipid profile, serum creatinine, uric acid, electrolytes, liver function enzymes, albumin) and determination of serum miR-192 and miR-25.

Two urine samples will be also collected to assess aliquots of 200 μl each (frozen at -80°C until required for quantitation) for determination of albumin:creatinine ratio and urine expression of miR-192 and miR-25. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04176276
Study type	Observational
Source	University of Pisa
Contact
Status	Completed
Phase
Start date	March 1, 2018
Completion date	March 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03239366` - A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population	Phase 2
Completed	`NCT04597229` - Efficacy of Multigrain Supplementation in Type II Diabetes Mellitus	N/A
Completed	`NCT03623139` - Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education in Type 2 Diabetes	N/A
Active, not recruiting	`NCT04599920` - Effects of Replacing Red Meat With Legumes on Biomarkers of Chronic Diseases in Healthy Men (Leg4Life)	N/A
Active, not recruiting	`NCT03422471` - Hypoglycemia and Autonomic Nervous System Function- B2	N/A
Completed	`NCT04382521` - A Text Message Intervention to Promote Health Behaviors in Cardiac Risk Conditions	N/A
Recruiting	`NCT04564391` - Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins	N/A
Recruiting	`NCT03458715` - The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin	Phase 4
Terminated	`NCT03278236` - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?	N/A
Completed	`NCT02974504` - Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes(EVERGREEN)	Phase 4
Completed	`NCT05053828` - Type 2 Diabetes With Antiplatelet Drugs
Not yet recruiting	`NCT03659383` - The Exploration of Optimal Treatment Scheme in Patients With Type 2 Diabetes Inadequately Controlled With Glargine	Phase 4
Completed	`NCT03542240` - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome	N/A
Completed	`NCT03657537` - Effects of Ketone Bodies on Cognition in Type 2 Diabetes	Phase 1
Completed	`NCT03979768` - Risk Assessment of Type 2 Diabetes in Pharmacies	N/A
Completed	`NCT03614039` - Effect of Probiotic and Smectite Gel on NAFLD	N/A
Active, not recruiting	`NCT04994288` - A Study of Efficacy and Safety of Supaglutide in Type 2 Diabetes Patients	Phase 2/Phase 3
Completed	`NCT03290768` - Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)	N/A
Enrolling by invitation	`NCT04088851` - "The Role of the Liver for Interorgan Metabolic Crosstalk in Type 2 Diabetes"	N/A
Completed	`NCT03643783` - Impact of Plasma Soluble Prorenin Receptor in Obese and Type 2 Diabetic Patients

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Determining Serum and Urinary Levels of miRNA 192 and miRNA 25 in Patients With and Without Type 2 Diabetes.

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms